A molecule called DLK1-35 may help glioblastoma resist temozolomide
Original title: DLK1-35 Contributes to Temozolomide Resistance in Glioblastoma Through the miR-140-3p/NHE1/ERK-MGMT Axis.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This looks like early lab work on tumor cells, and the study details have not even been posted yet.
The short version
This is early lab research into why the chemo drug temozolomide stops working for some people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.
What was studied. The full study is not available. Only the title was posted, with no abstract. The title says the team looked at a molecule called DLK1-35 and how it connects to glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary resisting temozolomide.
What they found. No abstract was posted, so the actual results are not available here. The title states that DLK1-35 helps glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary resist temozolomide. It also points to a chain of other molecules that may carry that effect. No numbers or details can be reported.
What this means, and what it doesn't
What it could mean: Temozolomide is a chemo drug used for glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. Over time it stops working for many people. Research like this tries to explain why that happens. It does not change any treatment available today.
What it doesn't mean: This is not a new treatment. It is early laboratory science about how tumor cells behave, and it is a long way from everyday care. There is no evidence here that anyone lived longer or felt better. It is not a promise of a cure. Because the abstract is missing, no one can judge how strong or reliable this work is.
Source: PubMed, July 23, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.